Option chain shows key data for Forte Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Forte Biosciences.

Forte Biosciences (NASDAQ:FBRX) Stock, Option Chain

Forte Biosciences

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

News

FBRX

Forte Biosciences shares are trading lower by 13.6% Monday afternoon. The company announced plans for the periodic resale of up to 9.5 million common stock shares by selling stockholders.

Why Forte Biosciences (FBRX) Stock Is Trading Lower

Movers

Forte Biosciences Inc. (NASDAQ: FBRX) shares are trading higher Wednesday. The company announced a $53 million private placement to fund the development of its autoimmune-focused drug candidate, FB102. Here&#39;s what you need to know.

Forte Biosciences Shares Are Soaring Today: What&#39;s Going On?

Crude-oil-4-logo

Earnings

Long Ideas

Intraday Update

Markets

Trading Ideas

PRFX

SOAR

XTKG

Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results

Forte Biosciences Inc

Press Releases

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences to Host R&D Day December 3, 2024

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

bluebird bio

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kronos Bio

Lantern Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

Prelude Therapeutics Incorporated - Common Stock

Comments

Forte Biosciences

Forte Biosciences (FBRX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell